BackY-Mabs Therapeutics Overview

Y-Mabs Therapeutics Receivables

Track Y-Mabs Therapeutics's receivables ($16M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$15.74M
↓ 58.81% YoYΔ $-22.48M vs prior year quarter

Peer average

Loading

Y-Mabs Therapeutics Receivables History

Loading

Y-Mabs Therapeutics vs. peers: Receivables Comparison

Loading

Y-Mabs Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Y-Mabs Therapeutics (YMAB) FAQ

The latest receivables for YMAB is $16M as of June 2025. That compares with $38M in the prior-year period — down 58.8% year over year. Investors often review this figure alongside Y-Mabs Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, YMAB's receivables moved from $38M to $16M — a 58.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Y-Mabs Therapeutics's operating scale or balance-sheet position.

A receivables figure of $16M for YMAB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting YMAB's receivables ($16M), review year-over-year change from $38M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Y-Mabs Therapeutics's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.